Compare VIOT & PYXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VIOT | PYXS |
|---|---|---|
| Founded | 2014 | 2018 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 87.0M | 71.6M |
| IPO Year | 2018 | 2021 |
| Metric | VIOT | PYXS |
|---|---|---|
| Price | $1.26 | $1.42 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | ★ 291.9K | 288.8K |
| Earning Date | 03-25-2026 | 03-23-2026 |
| Dividend Yield | ★ 5.50% | N/A |
| EPS Growth | N/A | ★ 3.03 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,858,000.00 |
| Revenue This Year | $42.19 | N/A |
| Revenue Next Year | $0.96 | N/A |
| P/E Ratio | $3.56 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.18 | $0.84 |
| 52 Week High | $4.33 | $5.55 |
| Indicator | VIOT | PYXS |
|---|---|---|
| Relative Strength Index (RSI) | 38.15 | 44.45 |
| Support Level | $1.22 | $1.29 |
| Resistance Level | $1.50 | $1.69 |
| Average True Range (ATR) | 0.09 | 0.11 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 33.33 | 24.32 |
Viomi Technology Co Ltd, along with its subsidiaries, specializes in the development and sale of Internet-of-Things-enabled smart home products, particularly focusing on home water solutions. The company markets its products in China and generates the majority of its revenue through the sale of smart water purification systems and other connected home devices designed to improve convenience and automation in residential settings. Its product offerings include water purification products, water heaters, smart water kettles, electric kettles, water filters, range hoods, gas stoves, and other small appliances.
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.